[Latest trend in consumption and utilization of schedule I and II controlled drugs - a nationwide population-based data in Taiwan

Chang RY, Wang SF, Wu MH, Her SH, Yang YH, Lai YH, Lai MC, Huang LY
Record ID 32018011350
Chinese (Mandarin)
Authors' objectives: The Pharmaceutical Plant of Controlled Drugs of Taiwan Food and Drug Administration (PPCD) supplies the schedule I and II controlled drugs required for medical treatment and scientific research in Taiwan. The purpose of this study was to analyze the latest trend in the consumption and utilization in National Health Insurance of schedule I and II controlled drugs was calculated using items of the PPCD, production according to the sales data in Taiwan Controlled Drugs Management Information System and the claim data in National Health Insurance Research Database.
Authors' results and conclusions: The utilization of schedule I and II controlled drugs accounts for about 90% of consumption, indicating that although clinical demand has increased year by year, the PPCD has supplied various formulations of schedule I and II controlled drugs according to clinical need. Additionally, the PPCD has been expanding capacity of research and development, and manufacturing, to provide new items of controlled drug, and to increase the self-manufactured products to meet clinical and patient needs.
Authors' recommendations: Our study shows that the medical consumption of schedule I and II controlled drugs increased from 762 S-DDD/m/d in 2015 to 929 S-DDD/m/d in 2019, growing by 22%, and utilization increased from 669 S-DDD/m/d to 838 S-DDD/m/d, growing by 25%.
Authors' methods: The purpose of this study was to analyze the latest trend in the consumption and utilization in National Health Insurance of schedule I and II controlled drugs was calculated using items of the PPCD, production according to the sales data in Taiwan Controlled Drugs Management Information System and the claim data in National Health Insurance Research Database.
Details
Project Status: Completed
URL for protocol: https://www.grb.gov.tw/search/planDetail?id=13793747
Year Published: 2023
URL for published report: https://jtp.taiwan-pharma.org.tw/155/137-148.html
English language abstract: An English language summary is available
Publication Type: Full HTA
MeSH Terms
  • Drug Utilization
  • Drug Utilization Review
  • Controlled Substances
Keywords
  • Schedule Ⅰ and Ⅱ controlled drugs
  • the claims trend of NHI
  • pharmaceutical plant of TFDA
Contact
Organisation Name: Center for Drug Evaluation
Contact Address: 3F.,No.465, Sec.6, Zhongxiao E. Rd., Taipei 11557, Taiwan. R.O.C.
Contact Name: Li Ying (Grace) Huang
Contact Email: lyhuang277@cde.org.tw
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.